Abstract
We investigated the combination effect of teicoplanin (TEIC) or vancomycin (VCM) and 6 β-lactams in vitro using 49 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from neonates who were admitted to the newborn intensive care unit. We combined TEIC with imipenem (IPM), meropenem (MEPM), panipenem (PAPM), cefpirome (CPR), flomoxef (FMOX), or sulbactam (SBT)/ampicillin (ABPC). Synergistic effects were noted in 16 to 48 strains. In particular, the combinations of TEIC and IPM, MEPM, PAPM, or FMOX showed synergistic effects in many strains. Furthermore, 3 strains did not respond to the combination of TEIC and CPR; however, none of the strains exhibited antagonism. Combination with VCM and the above β-lactams produced synergistic effects in 1 to 32 strains. No changes were seen in 1 to 17 strains, and 2 to 6 strains exhibited antagonism. These results suggest that, when combined with the β-lactams tested, TEIC exhibits more potent synergistic effects than VCM.
| Original language | English |
|---|---|
| Pages (from-to) | 95-101 |
| Number of pages | 7 |
| Journal | Japanese Journal of Chemotherapy |
| Volume | 54 |
| Issue number | 2 |
| Publication status | Published - 2006 Feb |
| Externally published | Yes |
Fingerprint
Keywords
- β-lactam
- Combination effect
- MRSA
- Teicoplanin
- Vancomycin
ASJC Scopus subject areas
- Pharmacology
Cite this
In vitro combination effect of glycopeptides and β-lactams against methicillin-resistant Staphylococcus aureus. / Sato, Yoshitake; Sando, Mitsuru; Iwata, Satoshi; Akita, Hironobu; Sunakawa, Keisuke.
In: Japanese Journal of Chemotherapy, Vol. 54, No. 2, 02.2006, p. 95-101.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro combination effect of glycopeptides and β-lactams against methicillin-resistant Staphylococcus aureus
AU - Sato, Yoshitake
AU - Sando, Mitsuru
AU - Iwata, Satoshi
AU - Akita, Hironobu
AU - Sunakawa, Keisuke
PY - 2006/2
Y1 - 2006/2
N2 - We investigated the combination effect of teicoplanin (TEIC) or vancomycin (VCM) and 6 β-lactams in vitro using 49 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from neonates who were admitted to the newborn intensive care unit. We combined TEIC with imipenem (IPM), meropenem (MEPM), panipenem (PAPM), cefpirome (CPR), flomoxef (FMOX), or sulbactam (SBT)/ampicillin (ABPC). Synergistic effects were noted in 16 to 48 strains. In particular, the combinations of TEIC and IPM, MEPM, PAPM, or FMOX showed synergistic effects in many strains. Furthermore, 3 strains did not respond to the combination of TEIC and CPR; however, none of the strains exhibited antagonism. Combination with VCM and the above β-lactams produced synergistic effects in 1 to 32 strains. No changes were seen in 1 to 17 strains, and 2 to 6 strains exhibited antagonism. These results suggest that, when combined with the β-lactams tested, TEIC exhibits more potent synergistic effects than VCM.
AB - We investigated the combination effect of teicoplanin (TEIC) or vancomycin (VCM) and 6 β-lactams in vitro using 49 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from neonates who were admitted to the newborn intensive care unit. We combined TEIC with imipenem (IPM), meropenem (MEPM), panipenem (PAPM), cefpirome (CPR), flomoxef (FMOX), or sulbactam (SBT)/ampicillin (ABPC). Synergistic effects were noted in 16 to 48 strains. In particular, the combinations of TEIC and IPM, MEPM, PAPM, or FMOX showed synergistic effects in many strains. Furthermore, 3 strains did not respond to the combination of TEIC and CPR; however, none of the strains exhibited antagonism. Combination with VCM and the above β-lactams produced synergistic effects in 1 to 32 strains. No changes were seen in 1 to 17 strains, and 2 to 6 strains exhibited antagonism. These results suggest that, when combined with the β-lactams tested, TEIC exhibits more potent synergistic effects than VCM.
KW - β-lactam
KW - Combination effect
KW - MRSA
KW - Teicoplanin
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=33645797571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645797571&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33645797571
VL - 54
SP - 95
EP - 101
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 2
ER -